CCR2/64I mutation detection in a HIV-1-positive patient with slow CD4 T-cell decline and delay in disease progression.
Chemokine receptor genetic mutations are among the factors which have been shown to influence human susceptibility to HIV-1 infection and progression. The CCR2-64I mutation has been shown to delay HIV-1 disease progression in some studies. Here we show evidence of delayed disease progression, reflected in maintenance of a stable viral load and a slow CD4 T-cell decline, in a patient with the CCR2-64I gene. We then consider the potential value of identifying these genetic defects in the era of fusion/entry inhibiting therapeutics.
Burton
Catherine T
CT
Department of Immunology, Imperial College, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Gotch
Frances M
FM
Imami
Nesrina
N
D000328:Adult; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology*; D015497:HIV-1; D006801:Humans; D009154:Mutation; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000235:genetics*
C515334:CCR2 protein, human; D054390:Receptors, CCR2; D019707:Receptors, Chemokine